The use of IFN therapy in patients infected with SARS-CoV-2 would therefore mimic the increased and sustained ZBP1 expression observed in the critically ill patients with COVID-19, which could result in multi-organ damage, cytokine storm and mortality in patients. The gene discussed is IFNA1; the disease is COVID-19.